Top Markets
#1 Derive Derive +32.37%
#2 Cross Cross +15.42%
#3 Glidr Glidr +10.10%
#4 Gama Token Gama Token +9.10%
#5 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.92%
#6 Palladium Network Palladium Network +6.09%
#7 Based Based +5.99%
#8 Geodnet Geodnet +5.11%
#9 龙虾 (Lobster) 龙虾 (Lobster) +5.09%
#10 Talus Network Talus Network +4.83%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Blue Water Vaccines, Inc. Blue Water Vaccines, Inc.

Blue Water Vaccines, Inc.

BWV
Rank in Stocks #36371
Blue Water Vaccines, Inc. (BWV) operates as a biotechnology firm dedicated to... Blue Water Vaccines, Inc. (BWV) operates as a biotechnology firm dedicated to the worldwide discovery and development of vaccines aimed at preventing infectious diseases. Currently in preclinical stages, their most prominent vaccine candidates are BWV-101, an influenza shot, and BWV-102, designed to counter H1 pre-pandemic threats. The company's developmental portfolio also includes other preclinical programs such as BWV-201, a vaccine addressing acute otitis media caused by Streptococcus pneumoniae; BWV-301, a combined vaccine for norovirus and rotavirus; and BWV-302, a dual-target vaccine for norovirus and malaria. Founded in 2018, BWV's operations are based in Cincinnati, Ohio.
Share Price
$0.1735
Last synced: 2024-01-16
Market Cap
$2.76M
Change (1 day)
-3.82%
Change (1 year)
0.00%
Country
US
Trade Blue Water Vaccines, Inc. (BWV)

Category

Healthcare
P/E ratio for Blue Water Vaccines, Inc. (BWV)
P/E ratio as of 2026 TTM: 0
According to Blue Water Vaccines, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Blue Water Vaccines, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.